12 December 2016 - The Scottish Medicines Consortium has today published advice accepting a medicine used to treat advanced prostate cancer for routine use by NHS Scotland.

Cabazitaxel (Jevtana), which can be used to treat late stage prostate cancer, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.

Following consideration under the PACE process, the Committee was unable to accept pertuzumab (Perjeta) for the routine treatment of certain types of breast cancer.

Ivacaftor (Kalydeco) for the treatment of cystic fibrosis in adults with the R117H genetic mutation was not recommended following review under the PACE process.

Pembrolizumab (Keytruda), which can be used to treat a small group of patients with advanced melanoma (skin cancer) who have previously been treated with another medicine, ipilimumab, was also not recommended.

Read SMC news article